Phase 2 N=20 Study of Nasal Insulin to Fight Forgetfulness - Device Study
Mild Cognitive Impairment · Cognitive Impairment
Primary: CSF Insulin Levels — 0.14; 0.15 microUnits/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=69 Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Oncology · Melanoma · Ovarian Cancer
Primary: Number of Participants Who Experienced AEs or SAEs — 5; 4; 8; 15 Participants
Phase 2 N=153 A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet
Celiac Disease
Primary: Change in Weekly Celiac Disease Symptom Diary (CDSD) Gastrointestinal (GI) Symptom Severity Score From Baseline to Week 12 — -0.128; -0.111 score on a scale — p==0.847
Phase 2 N=104 Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients With Liver Cancer
Hepatocellular Carcinoma
Primary: Treatment Response to Yttrium Y-90 Radioembolization — 2; 17; 17; 17 Participants
Phase 2 N=10 HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Primary: Number of Participants With a Treatment Response in the Modified Composite Assessment of Index Lesion Disease Severity (mCAILS) Score — 3; 1 Participants
Phase 2 N=6 Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Extensive Stage Small Cell Lung Carcinoma · Lung Adenocarcinoma · Recurrent Non-Small Cell Lung Carcinoma
Primary: Number of Phase 1 Patients Experiencing a DLT — 0; 0 Participants
Phase 2 N=21 Sleep Management And Recovery After Traumatic Brain Injury in Kids: Pilot Intervention of Melatonin
Traumatic Brain Injury · Critical Illness · Sleep
Primary: Sleep Disturbances Scale for Children — 55; 69; 64; 73 T-score
Phase 2 N=77 Smell in COVID-19 and Efficacy of Nasal Theophylline (SCENT 3)
COVID-19
Primary: Clinical Global Impression - Improvement Scale — 9; 9 Participants
Phase 2 N=30 Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder
Temporomandibular Disorder
Primary: Brief Pain Inventory (BPI) Pain Severity at 20 Weeks — 1.72; 1.42 score on a scale — p=0.567
Phase 2 N=68 Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Myeloid Leukemia, Chronic · Acute Myelogenous Leukemia · Myelodysplastic Syndromes (MDS)
Primary: GvHD Free Relapse Free Survival (GRFS) — 1; 1; 0; 9 Participants
Phase 2 N=15 Medications for Obstructive Sleep Apnea In Children With Down Syndrome
Obstructive Sleep Apnea · Down Syndrome
Primary: Obstructive Apnea-hypopnea Index (oAHI) — -3.79; -3.51 events per hour
Phase 2 N=80 Serologic Assay Validation and Proficiency Testing of HIL-214 in Adults
Gastroenteritis
Primary: Primary Immunogenicity for Panel Formation — 87.0; 72.7; 60.5; 98.7 Percentage of Participants
Phase 2 N=54 RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19
COVID-19
Primary: Total Protein Normal to Abnormal Transition — 0; 0 percentage of participants
Phase 2 N=280 A Phase 2 Bridging Study to Assess the New Formulation of ETVAX
Healty Volunteers · Preventable Disease, Vaccine
Primary: Vaccine Response — 116; 110 Participants
Phase 2 N=21 CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab
Intermediate Stage of Hepatocellular Carcinoma · Hepatocellular Carcinoma
Primary: Objective Response Rate (ORR) — 11 Participants